Gilbert Cisneros
Tickers in This Filing
Price Movement Since Trade
How each stock has moved from the trade date to the most recent close.
Share This Filing
All Transactions
Connected Legislative Activity
2 signalsThese bills and contracts share tickers or sectors with this filing's trades.
To amend subsection (q) of section 505 of the Federal Food, Drug, and Cosmetic Act to clarify the process for denying certain petitions whose primary purpose is to delay the approval of an application submitted under subsection (b)(2) or (j) of such section 505, and for other purposes.
HR8908 is an early-stage procedural bill that clarifies FDA's authority to deny citizen petitions intended solely to delay generic drug approvals. It has no direct funding, no spending authorization, and is at the earliest legislative stage (referred to committee). Market impact is minimal — the bill affects a narrow procedural mechanism that applies to a small subset of drug applications.
To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program.
HR8857 is an early-stage bill that would exempt engineered cyclic peptides from Medicare drug price negotiation. It has minimal near-term market impact due to its procedural status and lack of specific drug identification. No funding is authorized.
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.